agtx-2004

AGTX-2004 is a **peripherally-acting small molecule antagonist of the cannabinoid receptor type 1 (CB1R)**, under development by Agentix Corp for metabolic diseases including **type 2 diabetes mellitus, obesity, and non-alcoholic fatty liver disease (NAFLD)**[1][2][7][11][12][13][14]. Unlike earlier centrally-acting CB1R antagonists, AGTX-2004 is designed to *minimize blood-brain barrier penetration* and primarily restrict its action to peripheral tissues, as demonstrated by minimal CNS accumulation in pre-clinical imaging[12]. Its mechanism targets metabolic syndrome by lowering blood glucose, reducing body weight, and improving lipid profiles, with preclinical studies demonstrating efficacy in animal models compared to rimonabant[1]. AGTX-2004 has shown improved insulin sensitivity and sustained weight loss in these models, suggesting potential clinical advantages over older CB1R antagonists[1][12]. The drug was developed through collaborations and exclusive worldwide license agreements with Taiwan's National Health Research Institute and Research Triangle Institute[2][5][7]. The developer, Agentix Corp, has established Agentix Australia Pty Ltd to lead development and clinical trials. AGTX-2004 has completed FDA IND clearance, with Phase 1 safety and tolerability studies planned[2]. No significant accumulation in brain tissue has been observed, emphasizing its peripheral mechanism of action and intended safety improvements over first-generation CB1R antagonists[12].

Brand names

AGTX-2004AGTX2004AGTX 2004